Antibody-drug conjugate

CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma

Retrieved on: 
Tuesday, November 8, 2022
Sheba Medical Center, Neutralizing antibody, Nature, CSCS, Dean (education), MD, Patient, Population, Cancer, Antibody-drug conjugate, Regenerative medicine, Control, ADC, Hematology, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Doctor of Philosophy, Tic, National Center for Regenerative Medicine, Center, OTCQB, Tel Aviv University, CSC, Cancer stem cell, Medicine, Marketing, Research, Development, Fine chemical

REHOVOT, IsraelandBETHESDA, MD, Nov. 8, 2022 /PRNewswire/ --CNBX Pharmaceuticals Inc. (OTCQB: CNBX),a global leader in the development of cancer related medicine, announced today that it has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd.

Key Points: 
  • REHOVOT, IsraelandBETHESDA, MD, Nov. 8, 2022 /PRNewswire/ --CNBX Pharmaceuticals Inc. (OTCQB: CNBX),a global leader in the development of cancer related medicine, announced today that it has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd.
  • The TaGeza research team remains committed to the company, and co-founder Prof. Benjamin Dekel (MD, PhD) will continue to serve as the company's Chief Scientist; CNBX Chairman, Gabriel Yariv, to assume the position of TaGeza Biopharmaceuticals CEO.
  • TaGeza is a developer of next generation immunotherapy and cancer-targeted therapies.
  • He is also Associate Dean for Clinical Research Innovation and Development and Director of the Center of Regenerative Medicine, at Tel Aviv University.

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Retrieved on: 
Wednesday, November 2, 2022
Marketing, Initiate, GLOBE, Brain, Research, BOCA, IND, NIH, Neuroinflammation, PIN, Lymphoma, Private Securities Litigation Reform Act, Company, Review, FDA, Təsi, CMC, TNF, CEO, Trastuzumab, US Foods, Chemistry, TME, ASH, Program, Immunotherapy, Cell, Squamous cell carcinoma, AD, NASDAQ, Neoplasm, U.S. Securities and Exchange Commission, Multiple myeloma, Patient, Ovarian cancer, MCI, Cancer, Natural killer cell, Security (finance), Control, Quarter, SITC, Conference, Clinical trial, TRD, Disease, SAS, ADC, Inflammation, Woman, Better Access Scheme, NK, Antibody-drug conjugate, MUC4, Tumor microenvironment, Breast cancer, Biomarker, Society, Hypoxia, Cytokine, Food, Prostate, Leukemia, Process control block, Vaccine, Pharmaceutical industry, Medical device, Medical imaging, Renewable energy

BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, today reported its financial results for the quarter ended September 30, 2022 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, today reported its financial results for the quarter ended September 30, 2022 and provides a business update.
  • The second UK clinical site is due to be initiated in November 2022 and a third UK site is under evaluation.
  • Financial Results for the Quarter Ended September 30, 2022:
    Net loss attributable to common stockholders for the quarter ended September 30, 2022 was approximately $7.7 million, compared to approximately $9.5 million for the quarter ended September 30, 2021.
  • Other expense was approximately $0.3 million for the quarter ended September 30, 2022 compared to approximately $0.4 million during the quarter ended September 30, 2021.

Duality announced the appointment of Dr. Yver as Chairman of SAB

Retrieved on: 
Monday, October 3, 2022
Conjugation, ADC, Johnson & Johnson, Time, Drug development, Learning, Rhône-Poulenc, Technology, Reality, Disease, IND, CEO, Schering-Plough, Multimedia, Universitate metro station, AstraZeneca, Oncology, Daiichi Sankyo, Master, Safety, Development, Leadership, Patient, Control, Antibody-drug conjugate, Degenerative disease, University, Intellectual property, Board, Company, SAB, Fine chemical, Pharmaceutical industry, Duality

PRINCETON, N. J. and SHANGHAI, SUZHOU, China, Oct. 3, 2022 /PRNewswire/ --Duality Biotherapeutics, Inc. ("Duality" or "the Company") today announced the appointment of Dr. Antoine Yver as Chairman of SAB.

Key Points: 
  • PRINCETON, N. J. and SHANGHAI, SUZHOU, China, Oct. 3, 2022 /PRNewswire/ --Duality Biotherapeutics, Inc. ("Duality" or "the Company") today announced the appointment of Dr. Antoine Yver as Chairman of SAB.
  • Dr. Antoine Yver has more than 32 years of oncology development and clinical experience.
  • "We are delighted that Dr. Antoine Yver has joined Duality as Chair of our SAB.
  • These include DITAC (Duality Immune Toxin Antibody Conjugate) with significantly improved therapeutic window and DIMAC (Duality Immune Modulating Antibody Conjugate) with superior efficacy than traditional biologics.

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

Retrieved on: 
Monday, October 3, 2022
Cancer, ADCC, Doctor of Philosophy, ADC, Neoplasm, CD205, Boehringer Ingelheim, Clinical trial, Rhode Island Division of Commercial Licensing and Regulation, Antibody-drug conjugate, CEO, Amgen, NJ, Kite Pharma, Cytotoxicity, BMS, OXFORD, SAN, Patient, OBT, Wuxi, Therapy, Vaccine, IO

Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.

Key Points: 
  • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.
  • OBT will receive an undisclosed upfront and potential milestone payments and royalty payments on net product sales under the agreement.
  • Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody.
  • This represents the first major license agreement for OBT's IO programs to a world leader in the field of antibody-based oncology medicines.

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

Retrieved on: 
Monday, October 3, 2022
Cancer, ADCC, Doctor of Philosophy, ADC, Neoplasm, CD205, Boehringer Ingelheim, Clinical trial, Rhode Island Division of Commercial Licensing and Regulation, Antibody-drug conjugate, CEO, Amgen, NJ, Kite Pharma, Cytotoxicity, BMS, OXFORD, SAN, Patient, OBT, Wuxi, Therapy, Vaccine, IO

Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.

Key Points: 
  • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.
  • OBT will receive an undisclosed upfront and potential milestone payments and royalty payments on net product sales under the agreement.
  • Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody.
  • This represents the first major license agreement for OBT's IO programs to a world leader in the field of antibody-based oncology medicines.

EQS-News: DEFENCE THERAPEUTICS IS GRANTED PATENTS IN JAPAN AND ISRAEL EXPANDING ITS NOVEL ADC PLATFORM TECHNOLOGY IN THE FAST GROWING ANTIBODY-DRUG CONJUGATES MARKET

Retrieved on: 
Thursday, September 29, 2022
Control, Engineering, ADC, Recycling, Catastrophic illness, News, Antibody, Company, Therapy, Forward-looking statement, USD, Cancer, EQS, CEO, CSE, Technology, Vaccine, Cell, Antibody-drug conjugate, Diagnosis, Death, Japan Patent Office, Medicine, Infection, Toxicity, Defense, CAGR, Security (finance), Pharmaceutical industry, BC

261765 was published in the Israel Patents and Designs Journal on 1st August 2022.

Key Points: 
  • 261765 was published in the Israel Patents and Designs Journal on 1st August 2022.
  • The allowance of these new patents covering conjugated compounds permitting delivery of antibodies to the nucleus through the Company proprietary technology AccumTM.
  • "The Japan and Israel patents constitute an important milestone in protecting and expanding the commercial potential of AccumTM directly related to our ADC program.
  • Defences commitment to protect the Companys AccumTM technology platform innovation is crucial as its ADC development expands.

Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics

Retrieved on: 
Wednesday, September 28, 2022
Control, RCT, Research Corporation, Therapy, Lightspeed Venture Partners, ADC, Antibody-drug conjugate, IND, Company, Kings Cross, Atlas, Growth, Industry, Program, Patient, Cancer, Technology, Neutralizing antibody, Quality of life, Atlas Venture, Head, Research, HQ, Conjugation, Fine chemical, Management, Broad arrow

Financing led by Brandon Capital from its newly established UK operation; Forbion and Atlas Venture co-led the round

Key Points: 
  • Financing led by Brandon Capital from its newly established UK operation; Forbion and Atlas Venture co-led the round
    Investment signals Brandon Capital growth in the UK and Europe, from its HQ in Australia
    MELBOURNE, Australia and LONDON, Sept. 28, 2022 /PRNewswire/ -- Brandon Capital, Australasia's leading life science venture capital firm, is pleased to announce its leading role in the USD68m series A financing of Pheon Therapeutics (Pheon), that has emerged from stealth today.
  • The Pheon financing reflects Brandon Capital's ongoing growth and signals its goal to become an active international investor including in the UK and European markets.
  • Pheon is an emerging UK-based Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.
  • It has recently signed a collaboration with an Australian research member of the Brandon Capital managed Brandon BioCatalyst a unique network of over 50 leading medical research institutes.

Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics

Retrieved on: 
Wednesday, September 28, 2022
Control, RCT, Research Corporation, Therapy, Lightspeed Venture Partners, ADC, Antibody-drug conjugate, IND, Company, Kings Cross, Atlas, Growth, Industry, Program, Patient, Cancer, Technology, Neutralizing antibody, Quality of life, Atlas Venture, Head, Research, HQ, Conjugation, Fine chemical, Management, Broad arrow

Financing led by Brandon Capital from its newly established UK operation; Forbion and Atlas Venture co-led the round

Key Points: 
  • Financing led by Brandon Capital from its newly established UK operation; Forbion and Atlas Venture co-led the round
    Investment signals Brandon Capital growth in the UK and Europe, from its HQ in Australia
    MELBOURNE, Australia and LONDON, Sept. 28, 2022 /PRNewswire/ -- Brandon Capital, Australasia's leading life science venture capital firm, is pleased to announce its leading role in the USD68m series A financing of Pheon Therapeutics (Pheon), that has emerged from stealth today.
  • The Pheon financing reflects Brandon Capital's ongoing growth and signals its goal to become an active international investor including in the UK and European markets.
  • Pheon is an emerging UK-based Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.
  • It has recently signed a collaboration with an Australian research member of the Brandon Capital managed Brandon BioCatalyst a unique network of over 50 leading medical research institutes.

CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051

Retrieved on: 
Wednesday, September 7, 2022
AbbVie, CA, COVID-19, Patient, Cancer, Safety, Bristol Myers Squibb, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Therapeutic index, SAN, Bi-specific T-cell engager, Risk, CD71, Epithelial cell adhesion molecule, United, Camptothecin, Irinotecan, Conjugation, Conditional, Food, LinkedIn, Antibody-drug conjugate, Squamous cell carcinoma, Molecule, GLOBE, Control, Nasdaq, Company, Twitter, Neoplasm, ADC, Topotecan, Amgen, Clinical trial, CD166, CD3, Fine chemical, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the Company presented advances within its conditionally-activated ADC portfolio, including the next generation EpCAM-ADC, CX-2051, at the World ADC conference taking place September 6-9, 2022, in San Diego, CA.

Key Points: 
  • The momentum in the field of ADC therapeutics is incredibly exciting and holds great promise for the innovation and development of novel oncology therapeutics.
  • Topoisomerase-1 inhibitor-conjugated ADCs are showing impressive clinical activity, and importantly, the safety profiles of camptothecin and its derivatives have been well characterized.
  • CD71 and CD166 have historically been inaccessible targets for traditional ADCs due to their high expression levels on normal tissues.
  • CytomX has established strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb.

Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board

Retrieved on: 
Wednesday, September 7, 2022
People, MedImmune, AstraZeneca, CEO, Cancer, Antibody-drug conjugate, DABT, Asthma, Pharmaceutical industry, CSO, Antibody, Control, Biotechnology, Therapy, Atopic dermatitis, Advisory board, ADC, Merck, Johnson & Johnson, Immunotoxin, Drug development, Patient, Fine chemical, Vaccine

"I'm delighted to work with the team at Biosion to bolster their mission to deliver breakthrough therapeutics to patients globally."

Key Points: 
  • "I'm delighted to work with the team at Biosion to bolster their mission to deliver breakthrough therapeutics to patients globally."
  • "Biosion's SynTracer internalization platform is uniquely positioned to deliver fit-for-purpose monoclonal antibodies for ADC candidates, a next generation approach to targeting cancer."
  • Dr. Dixit was honored in 2020 by the World ADC Forum with its most prestigious award of Long Standing Contributor to ADCs.
  • Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and phase-I for atopic dermatitis.